# Simultaneous UPLC Assay for Oxitropium Bromide and Formoterol Fumarate Dihydrate in Pressurized Metered Dose Inhaler Products for Chronic Obstructive Pulmonary Disease

**Authors:** Serdar Seckin, Serap Saglik Aslan

PMC · DOI: 10.1093/jaoacint/qsad134 · Journal of AOAC International · 2023-12-18

## TL;DR

This paper introduces a fast and accurate UPLC method to measure two drugs in inhalers used for lung diseases.

## Contribution

The first UPLC method for simultaneous detection of Oxitropium Bromide and Formoterol Fumarate Dihydrate in inhaler products.

## Key findings

- The UPLC method achieved high precision and accuracy for both compounds with recovery rates over 96%.
- The method is faster and more cost-effective than traditional HPLC methods.
- The developed method is validated according to ICH guidelines and is selective despite matrix effects.

## Abstract

Oxitropium bromide (OB) and formoterol fumarate dihydrate (FFD) are inhaler molecules that are widely used in the treatment of chronic lung diseases.

The goal of this work was to create a reversed phase–ultra performance liquid chromatography (RP-UPLC) technique for assay and identification of OB and FFD, as well as identification and estimate of its associated compounds in pressurized metered dose inhaler product (pMDI).

Separation of oxitropium and formoterol peaks were enhanced on a C18 (50 × 2.1 mm × 1.7 μm) UPLC column with ethylene-bridged-hybrid technology, The mobile phase consists of buffer (0.07 M KH2PO4) and acetonitrile (80:20, v/v). The detector wavelength of 210 nm, flow rate of pump 0.6 mL/min, and oven temperature for column were set at 25°C. The injection volume was 10 μL. The method run time was 2 min. The mobile phase was used as the solvent.

Retention times (RTs) were 0.5 min for OB and 1.0 min for FFD. The assay analysis was linear range for all analytes within the range for concentrations 0.03—14.8 µg/mL of OB, 0.01–0.88 µg/mL of FFD. LOD values and LOQ values 0.009 and 0.026 µg/mL for OB and 0.003 and 0.009 µg/mL for FFD, respectively. Recoveries were obtained at 96.3% for OB and 97.2% for FFD. Precisions values were (as RSD, %) ≤1.5%.

With the UPLC method developed and validated according to the current ICH guidelines, it is possible to simultaneously detect OB and FFD of assay analysis in pMDI products accurately, precisely and selectively, independent of the matrix effect.

The present method is the first method in the literature based on the UPLC method for this purpose. The UPLC method is a time-saving method, it provides a faster and cheaper technique than the high performance liquid chromatography (HPLC) method.

## Linked entities

- **Chemicals:** Oxitropium bromide (PubChem CID 6917865), Formoterol fumarate dihydrate (PubChem CID 9919001)
- **Diseases:** Chronic Obstructive Pulmonary Disease (MONDO:0005002)

## Full-text entities

- **Diseases:** lung diseases (MESH:D008171), Chronic Obstructive Pulmonary Disease (MESH:D029424)
- **Chemicals:** acetonitrile (MESH:C032159), KH2PO4 (-), OB (MESH:C017590), FFD (MESH:D000068759), ethylene (MESH:C036216)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10907136/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10907136/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC10907136/full.md

---
Source: https://tomesphere.com/paper/PMC10907136